Skip to main content

Advertisement

Fig. 3 | BMC Cancer

Fig. 3

From: Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?

Fig. 3

A primary pancreatic neuroendocrine tumor with multiple hepatic metastases (G2) in one’s fourties. (a) Pre-treatment CT scan showing a large mass in the pancreatic body with a heterogeneous, hyperdense tumor (white arrow, size: 5.5 cm, density: 91 HU). (b) CT scan obtained 2.8 months after treatment of sunitinib showing that the lesion had become significantly smaller in size and more hypodense (white arrow, size: 2.5 cm, density: 44 HU). The percent change in tumor size and density was 55% and 52%, respectively, which was classified as PR by both the Choi criteria and RECIST. Samples obtained through endoscopic ultrasound-guided fine needle tissue acquisition before treatment showing a large trabecular structure, moderate cell atypia (c, original magnification, ×200, hematoxylin-eosin staining) and intense immunoreactivity for VEGFR2 (d, original magnification, ×200, IHC staining)

Back to article page